Anonymous Biopharma Company

Biopharmaceutical manufacturing environments depend on highly specialized automation systems that must meet strict FDA and GMP compliance requirements. For this enterprise-scale biopharma company, aging automation infrastructure had reached a critical inflection point: legacy components were approaching end-of-life, spare parts were becoming difficult to source, and vendor support was diminishing. In a regulated industry where unplanned downtime can jeopardize product quality, batch integrity, and ultimately patient safety, the risk of operating on obsolete technology was no longer acceptable. Without a structured remediation plan, the company faced potential production stoppages, failed audits, and costly emergency replacements.

The company engaged Rockwell Automation to implement a structured lifecycle services program designed specifically for regulated manufacturing environments. Rockwell conducted a comprehensive obsolescence risk assessment across the facility's automation assets, cataloging hardware and software components by lifecycle stage — from current through end-of-life. Based on this assessment, a prioritized remediation roadmap was developed, addressing the highest-risk systems first while minimizing disruption to ongoing production. Migration strategies were tailored to each asset class, including phased hardware replacements, firmware and software updates, and where applicable, modernization to current Rockwell platforms. The program incorporated change management protocols aligned with FDA 21 CFR Part 11 and GAMP 5 validation requirements, ensuring all modifications were fully documented and qualified before being placed back into service.

The lifecycle services engagement successfully mitigated the company's most critical obsolescence risks without interrupting commercial manufacturing operations. Key outcomes included:

• Production continuity maintained throughout the remediation program, with no unplanned downtime attributed to obsolescence-related failures during the engagement
• Regulatory compliance preserved, with all system changes executed under validated change control procedures meeting GMP standards
• Improved asset visibility, giving the operations and engineering teams a clear, current picture of automation lifecycle status across the facility
• Long-term support contracts secured for modernized systems, reducing future supply-chain exposure for critical spare parts

• Start with a formal asset lifecycle audit — without a complete inventory of automation hardware and software by lifecycle stage, prioritization is guesswork.
• Treat obsolescence as a compliance risk, not just a maintenance issue — in regulated pharma, aging systems can trigger warning letters if they can't be adequately supported or validated.
• Phase remediation around production schedules — coordinating replacements with planned shutdowns or campaign changeovers reduces validation burden and operational disruption.
• Engage the OEM early — vendor-led lifecycle programs often include preferential access to parts, migration tools, and validated upgrade paths that accelerate qualification.
• Document everything — in a GMP environment, the paper trail for system changes is as important as the changes themselves.